title: Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.
abstract: Novel cancer therapies targeting tumor angiogenesis have revolutionized treatment options in a variety of tumors. Specifically, VEGF signaling pathway (VSP) inhibitors have been introduced into clinical practice at a rapid pace over the last decade. It is becoming increasingly clear that VSP inhibitors can cause cardiovascular toxicities including hypertension, thrombosis, and heart failure. This review highlights these toxicities and proposes several strategies in their prevention and treatment. However, we recognize the dearth of data in this area and advocate a multi-disciplinary approach involving cardiologists and oncologists, as well as clinical and translational studies, in understanding and treating VSP-inhibitor associated toxicities.
authors.affiliation: Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, MA 02115, USA.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Bair
authors.forename: Toni K
authors.initials: TK
authors.lastname: Choueiri
authors.forename: Javid
authors.initials: J
authors.lastname: Moslehi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D054715:Cardiotoxins / Q000494:pharmacology; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000145:classification / Q000378:metabolism / Q000517:prevention & control; D006801:Humans; D054539:Medication Therapy Management; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000378:metabolism; D010348:Patient Care Team; D015398:Signal Transduction / Q000187:drug effects; D057170:Translational Research, Biomedical; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D054715:Cardiotoxins; D042461:Vascular Endothelial Growth Factor A